{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:35:06Z","timestamp":1791250506488,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Roche France"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.autrev.2014.08.036","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T14:10:59Z","timestamp":1409148659000},"page":"1055-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature."],"prefix":"10.1016","volume":"13","author":[{"given":"Romain","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Mah\u00e9vas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Galicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boutboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Moroch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Loustau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Guillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laeticia","family":"Languille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhi","family":"Khellaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.08.036_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.08.036_bb0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.autrev.2014.08.036_bb0015","article-title":"Safety and efficacy of rituximab in adult's immune thrombocytopenia (ITP): results of follow-up in 252 patients from the prospective French ITP-Ritux registry","volume":"122","author":"Khellaf","year":"2013","journal-title":"ASH Congr. Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0030","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","article-title":"Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.10413","article-title":"Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)","volume":"74","author":"Narang","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0045","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.08.036_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0060","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-007-0317-3","article-title":"Mexican hematology study group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis","volume":"86","author":"Garcia-Chavez","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00277-007-0335-1","article-title":"Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab","volume":"86","author":"Schweizer","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0609.2008.01100.x","article-title":"Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results","volume":"81","author":"Medeot","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-008-0574-9","article-title":"Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)","volume":"88","author":"Alasfoor","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0085","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.21439","article-title":"Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature","volume":"84","author":"Ling","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11239-008-0208-z","article-title":"The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura","volume":"27","author":"Pasa","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.autrev.2014.08.036_bb0100","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"De la Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2014.08.036_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-010-0753-z","article-title":"Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia","volume":"93","author":"Li","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0120","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0125","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0130","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12185-012-1206-7","article-title":"Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice","volume":"96","author":"\u010cervinek","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0135","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.23518","article-title":"Efficacy and safety of rituximab given at 1,000mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia","volume":"88","author":"Mah\u00e9vas","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0140","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.12102","article-title":"High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia","volume":"90","author":"G\u00f3mez-Almaguer","year":"2013","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.autrev.2014.08.036_bb0150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and 3 dexamethasone cycles provide responses similar to splenectomy in women and those with Immune Thrombocytopenia less than 2years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.08.036_bb0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","article-title":"Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment","volume":"146","author":"Wang","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2014.08.036_bb0160","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2008.07487.x","article-title":"Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response","volume":"144","author":"Parodi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00277-006-0123-3","article-title":"Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients","volume":"85","author":"Pe\u00f1alver","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2014.08.036_bb0180","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1532\/IJH97.E0518","article-title":"Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment","volume":"84","author":"Parodi","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0190","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2014.08.036_bb0195","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/08880010903271697","article-title":"Persistent antibody depletion after rituximab in three children with autoimmune cytopenias","volume":"26","author":"Adeli","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0200","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2141.2009.07715.x","article-title":"Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin","volume":"146","author":"Cooper","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0205","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2011-12-309153","article-title":"How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment","volume":"120","author":"Ghanima","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0220","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.autrev.2012.02.005","article-title":"Rituximab\u2014it was the best of times, it was the worst of times","volume":"11","author":"Isenberg","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0225","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","article-title":"Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases","volume":"12","author":"Kattah","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0230","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0235","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0240","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.10.013","article-title":"Rituximab \u2014 shadow, illusion or light?","volume":"11","author":"Van Vollenhoven","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.autrev.2011.11.007","article-title":"B-cell depleting agents for ANCA vasculitides: a new therapeutic approach","volume":"11","author":"G\u00f3mez-Puerta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0250","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.autrev.2013.11.006","article-title":"Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey","volume":"13","author":"Terrier","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0255","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0260","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome\u2014new directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0265","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0270","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.berh.2006.05.010","article-title":"B cell depletion therapy in rheumatic disease","volume":"20","author":"Edwards","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.036_bb0275","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.08.036_bb0280","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/0003-4819-118-9-199305010-00011","article-title":"NIH conference. New insights into common variable immunodeficiency","volume":"118","author":"Sneller","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.08.036_bb0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"10.1016\/j.autrev.2014.08.036_bb0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1054\/blre.2001.0185","article-title":"Hematologic complications of primary immune deficiencies","volume":"16","author":"Cunningham-Rundles","year":"2002","journal-title":"Blood Rev"},{"key":"10.1016\/j.autrev.2014.08.036_bb0295","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/587669","article-title":"Infections in 252 patients with common variable immunodeficiency","volume":"46","author":"Oksenhendler","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2014.08.036_bb0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","article-title":"The EUROclass trial: defining subgroups in common variable immunodeficiency","volume":"111","author":"Wehr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0305","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.md.0000133624.65946.40","article-title":"Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature","volume":"83","author":"Michel","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2014.08.036_bb0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2010-11-321695","article-title":"T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency","volume":"118","author":"Ochtrop","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.036_bb0320","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T03:57:47Z","timestamp":1538279867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1568997214001803"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.036","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}